@entity1496 -125 implants for XXXX .

@entity1 @entity1496 @entity263 @entity5 @entity344 @entity3750 @entity3
One hundred-thirteen @entity1 underwent @entity1496 -125 prostate implant and lymphadenectomy at Yale-New Haven Hospital from 1974 through 1980. The distribution by clinical stage was: 7 Stage @entity3750 , and 20 Stage C @entity1 . Ninety-four @entity1 had a negative lymphadenectomy (N-) and 19 @entity1 (17%) had @entity3 in the pelvic lymph nodes (N+). The actuarial 5-year survival for all 113 @entity1 was 87% (+/- 6%: 95% confidence limits). Sixty-five percent of our 113 @entity1 are disease free (NED) from 2 to 9 years following implant. Sixty-seven (N-) @entity1 with clinical Stage B disease, whose @entity5 were either well differentiated or moderately well differentiated, have an actuarial 5-year NED survival of 84% (+/- 8%). Twenty (N-) @entity1 with either clinical Stage C disease or poorly differentiated @entity5 have an actuarial 5-year NED survival of only 31% (+/- 20%). For the 19 (N+) @entity1 , the actuarial 5-year NED survival is 38% (+/- 22%). @entity5 control was 85% for all Stage B @entity1 and 75% for all Stage C @entity1 . Only 10 @entity1 (9%) have developed long-term @entity344 following their implant. @entity1496 -125 implant appears to be a reasonable alternate form of therapy in highly selected groups of @entity1 with @entity263 .
